Audentes Therapeutics (NASDAQ:BOLD) has been assigned a $37.00 price target by equities research analysts at HC Wainwright in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 9.96% from the company’s current price.
A number of other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. BidaskClub downgraded shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Bank of America reissued a “buy” rating and issued a $33.00 price target (up from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Leerink Swann reissued an “outperform” rating and issued a $29.00 price target (up from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. Finally, Raymond James Financial initiated coverage on shares of Audentes Therapeutics in a report on Thursday, October 12th. They issued a “market perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Audentes Therapeutics presently has a consensus rating of “Buy” and an average target price of $35.00.
Audentes Therapeutics (BOLD) opened at $33.65 on Thursday. The stock has a market cap of $957.16 and a PE ratio of -9.67. Audentes Therapeutics has a 12-month low of $13.90 and a 12-month high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.88). sell-side analysts expect that Audentes Therapeutics will post -3.5 earnings per share for the current year.
In other Audentes Therapeutics news, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock valued at $1,052,480 over the last ninety days. Insiders own 47.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in Audentes Therapeutics during the third quarter valued at about $143,000. Nationwide Fund Advisors lifted its stake in Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares in the last quarter. Trexquant Investment LP purchased a new stake in Audentes Therapeutics during the third quarter valued at about $295,000. State of Wisconsin Investment Board purchased a new stake in Audentes Therapeutics during the second quarter valued at about $210,000. Finally, Rhumbline Advisers purchased a new stake in Audentes Therapeutics during the second quarter valued at about $252,000. 78.95% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/11/audentes-therapeutics-bold-given-a-37-00-price-target-at-hc-wainwright.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.